Biohaven and Belgium’s KU Leuven in licensing deal

Biohaven acquired exclusive global rights to develop and sell a novel pain drug from Belgium’s KU Leuven university, the New Haven biotech reports.

The deal involves first-in-class transient receptor potential melastatin-3 (TRPM3) channel antagonists, a promising treatment for patients living with chronic pain disorders. The platform was discovered by bioscience researchers at KU Leuven, a Catholic research university in the city of Leuven, Belgium